Astra and Acasti throw the Amarin bulls more fodder
Amarin must hope that setbacks for Astrazeneca and Acasti show that in Vascepa it has the secret sauce.
Upcoming events – Karyopharm's myeloma expansion and Pfizer's biz dev nous
Karyopharm hopes to move Xpovio earlier in the multiple myeloma treatment sequence, and data are due for Akcea/Ionis’s triglyceride regulator, for which Pfizer paid a…
Vantage 2020 Preview – what’s in store for the biopharma sector?
Available to download for free now, our annual preview takes a data-driven look at 2020. Uncover biopharma’s biggest growth drivers, and see where the money is flowing.
Meril Life Sciences comes late to aortic valves
The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?
Cymabay is out, but for Genfit the band plays on
A day after seladelpar is canned over toxicity fears elafibranor passes a safety review, but should Genfit holders worry all the same?
Acasti plays catch-up to Amarin’s Vascepa
Two phase III studies could determine whether the Canadian biotech has an approvable product, but the setting will initially be narrow.
AHA 2019 – The Medicines Company reaches for the stars
Two more Orion trials have hit neatly and cleanly, and now success will be largely down to pricing.
Novo goes small with big Dicerna deal
Novo Nordisk takes its first step into RNA with a broad cardio-metabolic deal with Dicerna, the biggest sealed by the US biotech to date.
Amarin enters the home stretch
After an overwhelmingly positive adcom, the outstanding question around Vascepa is just how big the product might become.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.